A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV genotype 1 in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.
Image may be NSFW.
Clik here to view.
